The Anti Radiation Drugs Market is estimated to be valued at US$ 587.4 Mn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Anti radiation drugs are used to protect healthy cells from damage caused by radiation therapy. They help reduce the side effects of radiation such as fatigue, skin problems, and low blood cell counts. Anti radiation drugs work by repairing damaged DNA and preventing cell death. They play a vital role in cancer treatment by allowing higher doses of radiation to be used more safely and effectively.

Market key trends:

A key trend driving the anti radiation drugs market growth is the rising prevalence of cancer globally. According to WHO, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Radiation therapy is a common treatment method for various cancer types. Thus, growing cancer incidence rates increase the demand for anti radiation drugs to protect healthy cells from radiation-induced side effects during cancer treatment. Furthermore, increasing R&D investments by key players to develop novel and more effective anti radiation drugs also support the market growth. For instance, in 2021, RxBio Inc. received approval from FDA to initiate a phase 1/2 trial for its lead anti radiation drug RxB-100 to reduce oral mucositis in head and neck cancer patients undergoing radiation and chemotherapy.

The Global Anti Radiation Drugs Market Size is expected to witness high growth, exhibiting CAGR of 6.8% over the forecast period, due to increasing incidence of cancer globally. The market size for 2023 is estimated at US$ 587.4 Mn.

Regionally, North America is expected to dominate the anti-radiation drugs market through 2030. This is attributed to high healthcare expenditure, presence of major market players, and high awareness regarding the radiation effects and cancer treatment technologies. Asia Pacific region is anticipated to witness fastest growth during the forecast period owing to growing healthcare infrastructure, rise in cancer cases, and increasing focus on development of oncology treatment services in the region.

Key players operating in the anti-radiation drugs market include RxBio Inc., Annova Chem Inc., Medicom Healthcare Ltd., Onconova Therapeutics, Genome Protection Inc., Grace Therapeutics LLC, Amgen Inc., Partner Therapeutics Inc., Jubilant Life Sciences Ltd., Cipla Inc., Stium Inc., Soligenix Inc., Aeolus Pharmaceuticals, PharmaIN Corp, Immune Modulators Inc. Major players are focused on developing innovative drugs through strategic collaborations and acquisition strategies to strengthen their product pipelines and market positions.

Read more

http://digitalmarketinsights.weebly.com/blog/anti-radiation-drugs-market-is-estimated-to-witness-high-growth-owing-to-increasing-prevalence-of-cancer